NE‐100: A Novel Sigma Receptor Antagonist
1996; Wiley; Volume: 2; Issue: 2 Linguagem: Inglês
10.1111/j.1527-3458.1996.tb00299.x
ISSN1527-3458
AutoresShigeru Okuyama, Atsuro Nakazato,
Tópico(s)Synthesis of heterocyclic compounds
ResumoCNS Drug ReviewsVolume 2, Issue 2 p. 226-237 NE-100: A Novel Sigma Receptor Antagonist Shigeru Okuyama, Corresponding Author Shigeru Okuyama Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Ohmiya, Japan.Address correspondence and reprint requests to: Dr. Shigeru Okuyama, at 1st Labortory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan. Fax:048-652-7254Search for more papers by this authorAtsuro Nakazato, Atsuro Nakazato Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Ohmiya, Japan.Search for more papers by this author Shigeru Okuyama, Corresponding Author Shigeru Okuyama Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Ohmiya, Japan.Address correspondence and reprint requests to: Dr. Shigeru Okuyama, at 1st Labortory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan. Fax:048-652-7254Search for more papers by this authorAtsuro Nakazato, Atsuro Nakazato Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Ohmiya, Japan.Search for more papers by this author First published: June 1996 https://doi.org/10.1111/j.1527-3458.1996.tb00299.xCitations: 32AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Boyce B, Rupniak NMJ, Steventon G, Cook G, Iversen SD. Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interaction in primates. Brain Res 1991; 42: 115–121. CASPubMedWeb of Science®Google Scholar 2 Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia—Implications for schizophrenia and Parkinson's disease. Trends in Neurosci 1990; 13: 272–276. 10.1016/0166-2236(90)90108-M CASPubMedWeb of Science®Google Scholar 3 Chaki S, Tanaka M, Muramatsu M, Otomo S. NE-100, a novel potent σ ligand, preferentially binds to σ1, binding sites in guinea pig brain. Eur J Pharmacol 1994; 251: R1–R2. 10.1016/0014-2999(94)90453-7 CASPubMedWeb of Science®Google Scholar 4 Diana G, Scotti de Carolis A, Popoli P, Pezzola A, Sagratella S. Non-opioid antitussives potentiate some behavioural and EEG effects of N-methyl-D-aspartate channel blockers. Life Sci 1993; 52: 1547–1557. 10.1016/0024-3205(93)90055-8 CASPubMedWeb of Science®Google Scholar 5 Gao X-M, Kakigi T, Tamminga CA. Delayed phencyclidine effects on NMDA sensitive [3H]glutamate binding. Soc Neurosci Abstr 1992; 18: 978. Google Scholar 6 Gao X-M, Shirakawa O, Du F, Tamminga CA. Delayed regional metabolic action of phencyclidine. Eur J Pharmacol 1993; 241: 7–15. 10.1016/0014-2999(93)90926-9 CASPubMedWeb of Science®Google Scholar 7 Gewirtz GR, Gorman JM, Volavka J, et al. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacol 1994; 10: 37–40. 10.1038/npp.1994.5 CASPubMedWeb of Science®Google Scholar 8 Gilligan PJ, Tarn SW. Sigma receptor ligands: Potential drugs for the treatment of CNS disorders Drug News Perspectives 1994; 7: 13–18. Google Scholar 9 Grynne BH, Holmen AT, Maurset A. Evidence for distinct phencyclidine and SKF10047 receptors following detergent treatment of rat brain membranes. Pharmacol Toxicol 1992; 70: 25–30. 10.1111/j.1600-0773.1992.tb00420.x CASPubMedWeb of Science®Google Scholar 10 Holzman SG. Discriminative stimulus effects of the PCP/sigma-ligand (+)-N-allylnormetazocine in monkeys. Pharmacol Biochem Behav 1993; 44: 349–355. 10.1016/0091-3057(93)90473-7 PubMedWeb of Science®Google Scholar 11 Hudzik TJ, Slifer, BL. Interaction of sigma and PCP-like drugs on operant behaviors in the rat. Psychopharmacol 1992; 108: 115–122. 10.1007/BF02245295 CASPubMedWeb of Science®Google Scholar 12 Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. J Clin Psychiatry 1987; 9: 12–35. CASPubMedGoogle Scholar 13 Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301–1308. 10.1176/ajp.148.10.1301 CASPubMedWeb of Science®Google Scholar 14 Largent BL, Gundlach AL. Synder SH. Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hidroxyphenyl]-N-(l-propyl)piperidine, and [3H]-l-[l-(2-thienyl)cyclohexyl]piperidine. J Pharmacol Exp Ther 1986; 238: 739–748. CASPubMedWeb of Science®Google Scholar 15 Largent BL, Wikstrom H, Snowman AM, Synder SH. Novel antipsychotic drugs share high affinity for a receptors. Eur J Pharmacol 1988; 155: 345–347. 10.1016/0014-2999(88)90527-4 CASPubMedWeb of Science®Google Scholar 16 Levinson DF. Pharmacologic treatment of schizophrenia. Clin Ther 1991; 13: 326–352. CASPubMedWeb of Science®Google Scholar 17 Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517–532. CASPubMedWeb of Science®Google Scholar 18 Nakazato A, Sekiguchi Y, Ohta K, et al. Sigma-selective antagonists. 206th ACS National Meeting 1993; 181. Google Scholar 19 Ogawa S, Okuyama S, Araki H, Nakazato A, Otomo S. A rat model of phencyclidine psychosis. Life Sci 1994; 55: 1605–1610. 10.1016/0024-3205(94)00326-2 CASPubMedWeb of Science®Google Scholar 20 Ogawa S, Okuyama S, Araki H, Otomo S. Effect of NE-100, a novel σ receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur J Pharmacol 1994; 263: 9–15. 10.1016/0014-2999(94)90517-7 CASPubMedWeb of Science®Google Scholar 21 Ogawa S, Okuyama S, Araki H, Otomo S. The sigma-selective ligand NE-100 attenuates the effect of phencyclidine in a rat diving model. Gen Pharmacol 1995; 26: 177–182. 10.1016/0306-3623(94)00151-C CASPubMedWeb of Science®Google Scholar 22 Okuyama S, Chaki S, Yae T, Nakazato A, Muramatsu M. Autoradiographic characterization of binding sites for [3H]NE-100 in guinea pig brain. Life Sci 1995; 57: PL333–337. 10.1016/0024-3205(95)02184-K CASPubMedWeb of Science®Google Scholar 23 Okuyama S, Imagawa Y, Tomizawa K. Behavioral evidence for modulation by sigma ligands of (+)MK-801-induced hyperlocomotion in monoamine-depleted mice. Neuropharmacol 1996 (in press). 10.1016/0028-3908(95)00193-X CASWeb of Science®Google Scholar 24 Okuyama S, Imagawa Y, Ogawa S, et al. NE-100, a novel sigma receptor ligand: In vivo test. Life Sci 1993; 53: PL285–290. 10.1016/0024-3205(93)90588-T CASPubMedWeb of Science®Google Scholar 25 Okuyama S, Imagawa Y, Sakagawa T, et al. NE-100, a novel sigma receptor ligand: Effect on phency-clidine-induced behaviors in rats, dogs and monkeys. Life Sci 1994; 55: 133–138. 10.1016/0024-3205(94)00749-7 CASGoogle Scholar 26 Okuyama S, Ogawa S, Nakazato A, Tomizawa K. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci Lett 1995; 189: 60–62. 10.1016/0304-3940(95)11440-8 CASPubMedWeb of Science®Google Scholar 27 Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 1992; 13: 116–121. 10.1016/0165-6147(92)90041-4 CASPubMedWeb of Science®Google Scholar 28 Sagratella A, Scotti de Carolis A, Pezzola A, Popoli P. Behavioural and electroencephalographic interactions between haloperidol and PCP/sigma ligands in the rat. Psychopharmacol 1991; 105: 485–491. 10.1007/BF02244368 CASPubMedWeb of Science®Google Scholar 29 Schwarcz G, Halaris A, Dren A, Manberg P. Open-label evaluation of the novel antipsychotic compound BW 234U in chronic schizophrenics. Drug Dev Res 1985; 5: 387–393. 10.1002/ddr.430050412 Web of Science®Google Scholar 30 Sharp FR, Butman M. Wang S. et al. Haloperidol prevents induction of the hsp7O heat shock gene in neurons injured by phencyclidine (PCP), MK-801, and ketamine. J Neurosci Res 1992; 33: 605–616. 10.1002/jnr.490330413 CASPubMedWeb of Science®Google Scholar 31 Snyder SH, Largent BL. Receptor mechanisms in antipsychotic drug action: Focus on sigma receptors. J Neuropsychiatry 1989; 1: 7–15. 10.1176/jnp.1.1.7 CASPubMedGoogle Scholar 32 Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alteration with deficit syndrome. Arch Gen Psychiatry 1992; 49: 522–530. 10.1001/archpsyc.1992.01820070016003 CASPubMedWeb of Science®Google Scholar 33 Toru M, Kurumaji A, Ishimaru M. Excitatory amino acids: Implications for psychiatric disorders research. Life Sci 1994; 55: 1683–1699. 10.1016/0024-3205(94)00337-8 CASPubMedWeb of Science®Google Scholar 34 Tsung-Ping SU. Sigma receptors, putative links between neurons, endocrine, and immune systems. Eur J Biochem 1991; 200: 633–642. 10.1111/j.1432-1033.1991.tb16226.x CASPubMedWeb of Science®Google Scholar 35 Wadworth AN, Heel RC. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potentials in schizophrenia. Drugs 1990; 40: 867–879. Google Scholar 36 Wakatabe H, Nakano T, Tanaka T, et al. Phase I clinical study of NE-100, a new psychotropic drug for schizophrenia with selective sigma antagonist activity. 18th Annual Meeting of the Canadian College of Neuropsychopharmacology: A joint Meeting with the Japanese Society of Neuropsychopharmacology (Suppl.) 1995; 21. Google Scholar 37 Walker JM, Dowen WD, Walker FO, Matsumoto RR, Costa BD, Rice KC. Sigma receptor: Biology and function. Pharmacol Rev 1990; 42: 335–402. Google Scholar 38 Weissman AD, Su TP, Hedreen JC, London ED. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 1988; 247: 29–33. CASPubMedWeb of Science®Google Scholar 39 Weissman AD, Casanova MR Kleinman JE, London ED, De-Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites, in schizophrenia. Biol Psychiatry 1991; 29: 41–54. 10.1016/0006-3223(91)90209-5 CASPubMedWeb of Science®Google Scholar 40 Yamaguchi K, Nabeshima T, Kameyama T. Role of dopaminergic and serotonergic neuronal systems in the prefrontal cortex of rats in phencyclidine-induced behaviors. J Pharmacobio Dyn 1986; 9: 987–996. 10.1248/bpb1978.9.987 CASPubMedWeb of Science®Google Scholar 41 Yamamoto H, Yamamoto T, Sagi N, et al. NE-100, a novel sigma ligand: Effects of [3H]TCP binding to intact primary cultured neuronal cells. Life Sci 1994; 56: 39–43. 10.1016/0024-3205(94)00936-8 Google Scholar Citing Literature Volume2, Issue2June 1996Pages 226-237 ReferencesRelatedInformation
Referência(s)